Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
NCT07577583 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 32
Last updated 2026-05-11
Summary
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
Conditions
- B-cell Mediated Autoimmune Disorders
Interventions
- OTHER
-
No Intervention
No Intervention
Sponsors & Collaborators
-
TG Therapeutics, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 62 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2027-05-01
- Primary Completion
- 2039-12-01
- Completion
- 2039-12-01
More Related Trials
-
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
NCT04093622 ·Status: TERMINATED
-
Age-matched Reference Values for Circulating Natural Killer T-like Cells
NCT06450743 ·Status: COMPLETED ·Phase: NA
-
Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency
NCT07516002 ·Status: NOT_YET_RECRUITING
-
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy
NCT02931955 ·Status: COMPLETED
-
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
NCT06989541 ·Status: RECRUITING
-
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
NCT05292859 ·Status: COMPLETED
-
TIGIT in Patients With Chronic Myeloid Leukemia
NCT04818619 ·Status: UNKNOWN
-
Dendritic Cell Based Therapy for Breast Cancer Patients
NCT00935558 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study on Biomarkers of Immune-Related Adverse Events
NCT07527585 ·Status: NOT_YET_RECRUITING
-
CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NCT01995708 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Denileukin Diftitox on Immune System in CTCL Patients
NCT00254332 ·Status: COMPLETED
-
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
NCT00940004 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
NCT05304481 ·Status: RECRUITING ·Phase: PHASE2
-
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors
NCT03114566 ·Status: TERMINATED
-
Prospective Study of White Blood Cells
NCT04838171 ·Status: RECRUITING
-
T Cell Response in Hypersensitivity Syndrome
NCT00213447 ·Status: COMPLETED
-
Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors
NCT05118113 ·Status: UNKNOWN ·Phase: NA
-
A Study in Adult Subjects With Select Advanced Solid Tumors
NCT02583165 ·Status: COMPLETED ·Phase: PHASE1
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
NCT01686334 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Sequencing T-cells in Type I Diabetes Mellitus
NCT02040337 ·Status: COMPLETED
-
Regulatory T-cells After Subcutaneous Immunotherapy
NCT01830673 ·Status: COMPLETED
-
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
NCT01795378 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
NCT05995821 ·Status: RECRUITING
-
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539 ·Status: RECRUITING